Axsome Therapeutics Inc (AXSM) saw its loss widen to $8 million, or $0.41 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $5.87 million, or $0.31 a share. The company has not recorded any revenues for the current as well as previous quarter.
Operating loss for the quarter was $7.67 million, compared with an operating loss of $5.88 million in the previous year period.
“In the first quarter we continued to advance all of our clinical programs, which include three ongoing Phase 3 trials with our lead product candidates AXS-02 and AXS-05,” said Herriot Tabuteau, M.D., chief executive officer of Axsome. “The recently completed common stock offering bolsters our balance sheet and provides the financial resources to maintain our pipeline momentum.”
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]
